Skip to main content
TipRanks
Go Ultimate75% OFF

Compare Viking Therapeutics (VKTX) vs. Competitors

7,766 Followers

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
VKTXViking Therapeutics$24.77$3.30B-4.59-27.72%Strong BuyUnlock the VKTX analyst price target with TipRanks PremiumVKTXUnlock the VKTX top-analyst price target with TipRanks Premium
NAMSNewAmsterdam Pharma Company$18.41$2.34B-10.77-51.18%Strong BuyUnlock the NAMS analyst price target with TipRanks PremiumVKTX vs NAMSUnlock the NAMS top-analyst price target with TipRanks Premium
MLYSMineralys Therapeutics, Inc.$13.66$1.25B-3.13-67.38%Strong BuyUnlock the MLYS analyst price target with TipRanks PremiumVKTX vs MLYSUnlock the MLYS top-analyst price target with TipRanks Premium
GPCRStructure Therapeutics, Inc. Sponsored ADR$16.13$1.22B-4.13-53.03%Strong BuyUnlock the GPCR analyst price target with TipRanks PremiumVKTX vs GPCRUnlock the GPCR top-analyst price target with TipRanks Premium
KLRAKailera Therapeutics, Inc.$11.02$1.50B-3.64-57.62%Strong BuyUnlock the KLRA analyst price target with TipRanks PremiumVKTX vs KLRAUnlock the KLRA top-analyst price target with TipRanks Premium
PBLSParabilis Medicines, Inc.$27.44$3.46B-14.75-13.16%Strong BuyUnlock the PBLS analyst price target with TipRanks PremiumVKTX vs PBLSUnlock the PBLS top-analyst price target with TipRanks Premium

Performance Comparison

-100%-50%0%50%100%150%200%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
VKTXViking Therapeutics24.77-9.88-28.51%
NAMSNewAmsterdam Pharma Company18.41-20.90-53.17%
MLYSMineralys Therapeutics, Inc.13.66-28.94-67.93%
GPCRStructure Therapeutics, Inc. Sponsored ADR16.13-19.17-54.31%
KLRAKailera Therapeutics, Inc.11.02-14.98-57.62%
PBLSParabilis Medicines, Inc.27.44-4.16-13.16%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts